EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY 4.0

Rapid and long‐lasting efficacy of high‐dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review

Kanako Higashi, Yuri Sonoda, Noriyuki Kaku iD, Fumihiko Fujii, Fumiya Yamashita, Sooyoung Lee, Vlad Tocan, Go Ebihara, Wakato Matsuoka, Kenichi Tetsuhara, Motoshi Sonoda, Pin Fee Chong und 17 weitere

Molecular Genetics & Genomic Medicine · 2024

DOI: 10.1002/mgg3.2427 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Kanako Higashi und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Gaucher Disease, Ambroxol, Lysosomal Storage Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Sciences (JSPS) KAKENHI, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gaucher disease (GD) is a lysosomal storage disorder caused by a deficiency in the GBA1 ‐encoded enzyme, β‐glucocerebrosidase . Enzyme replacement therapy is ineffective for neuronopathic Gaucher disease (nGD). High‐dose ambroxol has been administered as an alternative treatment for a group of patients with nGD. However, little is known about the clinical indication and the long‐term outcome of patients after ambroxol therapy. We herein report a case of a female patient who presented with a progressive disease of GD type 2 from 11 months of age and had the pathogenic variants of p.L483P (formerly defined as p.L444P) and p.R502H (p.R463H) in GBA1 . A combined treatment of imiglucerase with ambroxol started improving the patient's motor activity in 1 week, while it kept the long‐lasting effect of preventing the deteriorating phenotype for 30 months. A literature review identified 40 patients with nGD, who had received high‐dose ambroxol therapy. More than 65% of these patients favorably responded to the molecular chaperone therapy, irrespective of p.L483P homozygous, heterozygous or the other genotypes. These results highlight the long‐lasting effect of ambroxol‐based chaperone therapy for patients with an expanding spectrum of mutations in GBA1 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseaseAmbroxolLysosomal Storage DiseasesHumansFemaleCombined Modality TherapyMolecular Chaperones

Stichwörter der Autor:innen

Gaucher diseaseambroxolchaperonegenotypeglucocerebrosidasetherapy

Substanzen

AmbroxolMolecular Chaperones

Autor:innen und Institutionen

  • Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Emergency and Critical Care Center, Kyushu University Hospital, Fukuoka, Japan.
  • Department of Pediatrics, National Hospital Organization Fukuoka Higashi Medical Center, Koga, Japan.
  • Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Clinical Chemistry and Laboratory of Medicine, Kyushu University Hospital, Fukuoka, Japan.

ORCID-Profile: Noriyuki Kaku, Yasunari Sakai

Förderung

  • Japan Society for the Promotion of Sciences (JSPS) KAKENHI
  • Japan Society for the Promotion of Science

Zitieren

APA

Higashi, K., Sonoda, Y., Kaku, N., Fujii, F., Yamashita, F., Lee, S., Tocan, V., Ebihara, G., Matsuoka, W., Tetsuhara, K., Sonoda, M., Chong, P. F., Mushimoto, Y., Kojima-Ishii, K., Ishimura, M., Koga, Y., Fukuta, A., Tsuchihashi, N. A., Kikuchi, Y., …, & Ohga, S. (2024). Rapid and long‐lasting efficacy of high‐dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.2427

Vancouver

Higashi K, Sonoda Y, Kaku N, Fujii F, Yamashita F, Lee S, et al. Rapid and long‐lasting efficacy of high‐dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.2427

BibTeX
@article{Higashi2024,
  author = {Higashi, Kanako and Sonoda, Yuri and Kaku, Noriyuki and Fujii, Fumihiko and Yamashita, Fumiya and Lee, Sooyoung and Tocan, Vlad and Ebihara, Go and Matsuoka, Wakato and Tetsuhara, Kenichi and Sonoda, Motoshi and Chong, Pin Fee and Mushimoto, Yuichi and Kojima-Ishii, Kanako and Ishimura, Masataka and Koga, Yuhki and Fukuta, Atsuhisa and Tsuchihashi, Nana Akagi and Kikuchi, Yoshikazu and Karashima, Takahito and Sawada, Takaaki and Hotta, Taeko and Yoshimitsu, Makoto and Terazono, Hideyuki and Tajiri, Tatsuro and Nakagawa, Takashi and Sakai, Yasunari and Nakamura, Kimitoshi and Ohga, Shouichi},
  title = {Rapid and long‐lasting efficacy of high‐dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review},
  journal = {Molecular Genetics & Genomic Medicine},
  year = {2024},
  doi = {10.1002/mgg3.2427}
}
Kostenlos starten →